Related Experiment Video
Updated: Jul 18, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
The use of HER2 modulation in the adjuvant setting
Peter H Johnson1, Francisco J Esteva
1Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77230-1439, USA.
Current Oncology Reports
|December 14, 2006
Summary
HER2-positive breast cancer treatment has improved significantly. Trastuzumab, an antibody targeting HER2 protein, enhances survival rates for early-stage patients when combined with chemotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Genetics
Background:
- HER2/neu gene amplification is a known indicator of poor prognosis in breast cancer.
- HER2 protein overexpression occurs in about 25% of invasive breast cancer cases.
- HER2-positive breast cancer has historically been associated with aggressive disease progression.
Purpose of the Study:
- To evaluate the efficacy of trastuzumab in treating HER2-positive breast cancer.
- To assess the impact of trastuzumab on survival rates in early-stage breast cancer patients.
Main Methods:
- Conducted randomized phase III clinical trials.
- Administered trastuzumab in combination with chemotherapy or sequentially after chemotherapy.
- Monitored disease-free survival and overall survival rates.
Main Results:
- Trastuzumab significantly improved disease-free survival.
- Trastuzumab significantly improved overall survival rates.
- These benefits were observed in patients with early-stage HER2-positive breast cancer.
Conclusions:
- Trastuzumab is a highly effective therapy for HER2-positive breast cancer.
- Integrating trastuzumab into adjuvant therapy transforms HER2-driven breast cancer into a curable subtype.
- Trastuzumab represents a major advancement in managing HER2-positive breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...